PedAM

Pediatric Disease Annotations & Medicines


	hematuria

Disease ID	1666
Disease	hematuria
Definition	Presence of blood in the urine.
Synonym	blood - urine - symptom blood hematuria urine blood in urine blood in urine (& symptom) blood in urine (& symptom) (finding) blood in urine (finding) blood in urine - haematuria blood in urine - haematuria (& [symptom]) blood in urine - haematuria (& [symptom]) (finding) blood in urine - hematuria blood in urine - hematuria (& [symptom]) blood in urine - hematuria (disorder) blood in urine - symptom blood urine haematuria haematuria (disorder) haematuria - symptom haematuria [ambiguous] haematuria nos haematuria nos (disorder) haematuria syndrome hematuria - symptom hematuria [disease/finding] hematuria nos hematuria nos (finding) hematuria syndrome hematuria syndrome (disorder) hematuria syndrome, nos hematuria urine blood hematuria, unspecified hematurias syndrome hematuria urine - blood - symptom urine blood
ICD10	ICD10CM:R31.9
UMLS	C0018965
MeSH	D006417
SNOMED-CT	SNOMEDCT_US_2016_09_01:34436003;SNOMEDCT_US_2016_09_01:53298000
Comorbidity	UMLS \| Disease \| Sentences' Count(Total Sentences:80) C0033687 \| proteinuria \| 47 C0022658 \| nephropathy \| 7 C0010692 \| cystitis \| 7 C0035078 \| renal failure \| 7 C0017661 \| iga nephropathy \| 7 C0005684 \| bladder cancer \| 6 C0027726 \| nephrotic syndrome \| 6 C0020538 \| hypertension \| 4 C0020295 \| hydronephrosis \| 4 C0022658 \| renal disease \| 4 C0027697 \| nephritis \| 4 C0022660 \| acute renal failure \| 3 C0085692 \| hemorrhagic cystitis \| 3 C0034359 \| pyuria \| 3 C0027707 \| interstitial nephritis \| 3 C0002871 \| anemia \| 3 C0376358 \| prostate cancer \| 2 C0018920 \| cavernous hemangioma \| 2 C0042075 \| uropathy \| 2 C1565489 \| renal insufficiency \| 2 C0178879 \| obstructive uropathy \| 2 C0020541 \| portal hypertension \| 2 C0392525 \| nephrolithiasis \| 2 C0039730 \| thalassemia \| 2 C0003857 \| arteriovenous malformation \| 2 C0002726 \| amyloidosis \| 2 C0017658 \| glomerulonephritis \| 2 C0037054 \| sickle cell trait \| 2 C0002895 \| sickle cell disease \| 2 C0018916 \| hemangiomas \| 2 C0034150 \| purpura \| 2 C0036323 \| schistosomiasis \| 2 C0011847 \| diabetes \| 2 C0022658 \| nephropathies \| 2 C0042769 \| virus infection \| 1 C0005745 \| ptosis \| 1 C0011849 \| diabetes mellitus \| 1 C0003467 \| anxiety \| 1 C0021831 \| bowel disease \| 1 C0018916 \| hemangioma \| 1 C0022661 \| chronic renal failure \| 1 C0041333 \| genitourinary tuberculosis \| 1 C0007642 \| cellulitis \| 1 C0036472 \| scrub typhus \| 1 C0007138 \| urothelial carcinoma \| 1 C0031117 \| peripheral neuropathy \| 1 C0178879 \| urinary tract obstruction \| 1 C0042384 \| vasculitis \| 1 C0021400 \| influenza \| 1 C0040015 \| glanzmann's thrombasthenia \| 1 C0040015 \| thrombasthenia \| 1 C1332965 \| congenital mesoblastic nephroma \| 1 C0041332 \| urinary tuberculosis \| 1 C0023890 \| cirrhosis \| 1 C0079731 \| b-cell lymphoma \| 1 C0041349 \| tubulointerstitial nephritis \| 1 C0019069 \| hemophilia \| 1 C0005818 \| thrombocytopathy \| 1 C0004659 \| bacteriuria \| 1 C0030499 \| parasitic diseases \| 1 C0011991 \| diarrhea \| 1 C0031090 \| periodontal disease \| 1 C0079744 \| diffuse large b-cell lymphoma \| 1 C0600139 \| carcinoma of the prostate \| 1 C0442874 \| neuropathy \| 1 C0042075 \| urologic diseases \| 1 C0042075 \| urologic disease \| 1 C0021390 \| inflammatory bowel disease \| 1 C0040034 \| thrombocytopenia \| 1 C0041471 \| typhus \| 1 C0007138 \| transitional cell carcinoma \| 1 C0024299 \| lymphoma \| 1 C0034152 \| henoch-schonlein purpura \| 1 C0008497 \| choriocarcinoma \| 1 C0014175 \| endometriosis \| 1 C0029089 \| ophthalmoplegia \| 1 C0030499 \| parasitic disease \| 1 C0022658 \| renal diseases \| 1 C0002986 \| fabry's disease \| 1 C0007102 \| colon cancer \| 1
Curated Gene	Entrez_id \| Symbol \| Resource(Total Genes:5) POMC \| 5443 \| CTD_human PLAU \| 5328 \| CTD_human F7 \| 2155 \| CTD_human ASPG \| 374569 \| CTD_human LMX1B \| 4010 \| CTD_human
Inferring Gene	(Waiting for update.)
Text Mined Gene	(Waiting for update.)
Locus	(Waiting for update.)

Disease ID	1666
Disease	hematuria
Integrated Phenotype	(Waiting for update.)
Text Mined Phenotype	HPO \| Name \| Sentences' Count(Total Phenotypes:75) HP:0000093 \| Proteinuria \| 47 HP:0012531 \| Pain \| 18 HP:0030157 \| Flank pain \| 11 HP:0000083 \| Renal insufficiency \| 9 HP:0100518 \| Painful or difficult urination \| 7 HP:0001919 \| Acute renal failure \| 7 HP:0000100 \| Nephrosis \| 6 HP:0012595 \| Mild proteinuria \| 6 HP:0009725 \| Bladder neoplasm \| 6 HP:0000112 \| Nephropathy \| 6 HP:0012587 \| Gross hematuria \| 6 HP:0002027 \| Abdominal pain \| 5 HP:0000822 \| Hypertension \| 4 HP:0001945 \| Fever \| 4 HP:0000123 \| Nephritis \| 4 HP:0000126 \| Hydronephrosis \| 4 HP:0012085 \| High urine neutrophil count \| 3 HP:0002573 \| Bloody diarrhea \| 3 HP:0000787 \| Renal calculi \| 3 HP:0001903 \| Anemia \| 3 HP:0001970 \| Interstitial nephritis \| 3 HP:0000969 \| Dropsy \| 2 HP:0012125 \| Prostate cancer \| 2 HP:0012721 \| Venous malformations \| 2 HP:0001048 \| Cavernous angioma \| 2 HP:0003259 \| Increased serum creatinine \| 2 HP:0012592 \| Albuminuria \| 2 HP:0002617 \| Aneurysmal dilatation \| 2 HP:0000099 \| Glomerular nephritis \| 2 HP:0011947 \| Respiratory infection \| 2 HP:0002664 \| Neoplasia \| 2 HP:0100026 \| Arteriovenous malformation \| 2 HP:0002615 \| Low blood pressure \| 2 HP:0000979 \| Purpura \| 2 HP:0008711 \| Benign prostatic hypertrophy \| 2 HP:0030731 \| Carcinoma \| 2 HP:0011034 \| Amyloid disease \| 2 HP:0001409 \| Portal hypertension \| 2 HP:0012597 \| Heavy proteinuria \| 2 HP:0010787 \| Genital tumor \| 1 HP:0003073 \| Hypoalbuminaemia \| 1 HP:0001824 \| Weight loss \| 1 HP:0002014 \| Diarrhea \| 1 HP:0001649 \| Tachycardia \| 1 HP:0003774 \| End-stage renal failure \| 1 HP:0002668 \| Paragangliomas \| 1 HP:0000819 \| Diabetes mellitus \| 1 HP:0100768 \| Choriocarcinoma \| 1 HP:0012593 \| Nephrotic range proteinuria \| 1 HP:0001873 \| Low platelet count \| 1 HP:0000020 \| Bladder incontinence \| 1 HP:0002665 \| Lymphoma \| 1 HP:0001250 \| Seizures \| 1 HP:0001028 \| Strawberry mark \| 1 HP:0000508 \| Drooping upper eyelid \| 1 HP:0001744 \| Splenomegaly \| 1 HP:0001394 \| Hepatic cirrhosis \| 1 HP:0003077 \| Hyperlipidemia \| 1 HP:0000282 \| Facial puffiness \| 1 HP:0000739 \| Anxiety \| 1 HP:0009830 \| Peripheral neuritis \| 1 HP:0011944 \| Small vessel vasculitis \| 1 HP:0200058 \| Angiosarcoma \| 1 HP:0000602 \| Ophthalmoplegia \| 1 HP:0003076 \| Glucosuria \| 1 HP:0012461 \| Bacteria in urine \| 1 HP:0002633 \| Vasculitis \| 1 HP:0012596 \| Moderate proteinuria \| 1 HP:0012735 \| Coughing \| 1 HP:0030127 \| Endometriosis \| 1 HP:0012191 \| B-cell lymphoma \| 1 HP:0100520 \| Oliguria \| 1 HP:0003419 \| Low back pain \| 1 HP:0003003 \| Colon cancer \| 1 HP:0100881 \| Congenital mesoblastic nephroma \| 1

Disease ID	1666
Disease	hematuria
Manually Symptom	(Waiting for update.)
Text Mined Symptom	(Waiting for update.)

Manually Genotype(Total Text Mining Genotypes:0)
(Waiting for update.)

All Snps(Total Genotypes:0)
(Waiting for update.)

GWASdb Annotation(Total Genotypes:0)
(Waiting for update.)

GWASdb Snp Trait(Total Genotypes:0)
(Waiting for update.)

Mapped by lexical matching(Total Items:0)
(Waiting for update.)

Mapped by homologous gene(Total Items:0)
(Waiting for update.)

Chemical(Total Drugs:45)
CUI	ChemicalName	ChemicalID	CasRN	DiseaseName	DiseaseID	DirectEvidence	PubMedIDs
C0018965	acetylcysteine	D000111	616-91-1	hematuria	MESH:D006417	therapeutic	6836328
C0018965	aminocaproic acid	D015119	60-32-2	hematuria	MESH:D006417	marker/mechanism	3812474
C0018965	amitriptyline	D000639	50-48-6	hematuria	MESH:D006417	marker/mechanism	6703117
C0018965	baclofen	D001418	1134-47-0	hematuria	MESH:D006417	marker/mechanism	17924939
C0018965	bleomycin	D001761	11056-06-7	hematuria	MESH:D006417	marker/mechanism	9572663
C0018965	busulfan	D002066	55-98-1	hematuria	MESH:D006417	marker/mechanism	12913734
C0018965	caffeine	D002110	1958/8/2	hematuria	MESH:D006417	marker/mechanism	2240058
C0018965	carbenicillin	D002228	4697-36-3	hematuria	MESH:D006417	marker/mechanism	760523
C0018965	carboprost tromethamine	C062843	58551-69-2	hematuria	MESH:D006417	therapeutic	2369708
C0018965	carmustine	D002330	154-93-8	hematuria	MESH:D006417	marker/mechanism	6134004
C0018965	cephalexin	D002506	15686-71-2	hematuria	MESH:D006417	marker/mechanism	1242194
C0018965	chlorambucil	D002699	305-03-3	hematuria	MESH:D006417	marker/mechanism	1138180
C0018965	ciprofloxacin	D002939	85721-33-1	hematuria	MESH:D006417	marker/mechanism	2931381
C0018965	clozapine	D003024	5786-21-0	hematuria	MESH:D006417	marker/mechanism	9669191
C0018965	cyclophosphamide	D003520	50-18-0	hematuria	MESH:D006417	marker/mechanism	10507982
C0018965	cyclophosphamide	D003520	50-18-0	hematuria	MESH:D006417	therapeutic	14563468
C0018965	cyclosporine	D016572	59865-13-3	hematuria	MESH:D006417	marker/mechanism	12913734
C0018965	cisplatin	D002945	15663-27-1	hematuria	MESH:D006417	marker/mechanism	9572663
C0018965	epirubicin	D015251	56420-45-2	hematuria	MESH:D006417	marker/mechanism	7598036
C0018965	ethosuximide	D005013	77-67-8	hematuria	MESH:D006417	marker/mechanism	9776542
C0018965	fluorouracil	D005472	51-21-8	hematuria	MESH:D006417	therapeutic	2996749
C0018965	foscarnet	D017245	4428-95-9	hematuria	MESH:D006417	marker/mechanism	10231404
C0018965	glutathione	D005978	70-18-8	hematuria	MESH:D006417	therapeutic	2773078
C0018965	griseofulvin	D006118	126-07-8	hematuria	MESH:D006417	marker/mechanism	2237566
C0018965	ifosfamide	D007069	3778-73-2	hematuria	MESH:D006417	marker/mechanism	1277203
C0018965	ifosfamide	D007069	3778-73-2	hematuria	MESH:D006417	therapeutic	6106781
C0018965	indinavir	D019469	150378-17-9	hematuria	MESH:D006417	marker/mechanism	10197375
C0018965	indomethacin	D007213	53-86-1	hematuria	MESH:D006417	marker/mechanism	7880236
C0018965	ivermectin	D007559	70288-86-7	hematuria	MESH:D006417	marker/mechanism	8555762
C0018965	mesna	D015080	19767-45-4	hematuria	MESH:D006417	marker/mechanism	12913734
C0018965	mesna	D015080	19767-45-4	hematuria	MESH:D006417	therapeutic	11450158
C0018965	methotrexate	D008727	1959/5/2	hematuria	MESH:D006417	marker/mechanism	12913734
C0018965	metoprolol	D008790	37350-58-6	hematuria	MESH:D006417	marker/mechanism	8554013
C0018965	mitomycin	D016685	1950/7/7	hematuria	MESH:D006417	therapeutic	2996749
C0018965	morphine	D009020	57-27-2	hematuria	MESH:D006417	marker/mechanism	8225663
C0018965	nafcillin	D009254	147-52-4	hematuria	MESH:D006417	marker/mechanism	7431606
C0018965	ofloxacin	D015242	82419-36-1	hematuria	MESH:D006417	marker/mechanism	8239258
C0018965	omeprazole	D009853	73590-58-6	hematuria	MESH:D006417	marker/mechanism	7802778
C0018965	oxytetracycline	D010118	79-57-2	hematuria	MESH:D006417	marker/mechanism	7364640
C0018965	propylthiouracil	D011441	51-52-5	hematuria	MESH:D006417	marker/mechanism	12521217
C0018965	rifampin	D012293	13292-46-1	hematuria	MESH:D006417	marker/mechanism	20497752
C0018965	sulfadiazine	D013411	68-35-9	hematuria	MESH:D006417	marker/mechanism	3389358
C0018965	valproic acid	D014635	99-66-1	hematuria	MESH:D006417	marker/mechanism	3124010
C0018965	vincristine	D014750	-	hematuria	MESH:D006417	marker/mechanism	12748258
C0018965	vindesine	D014751	53643-48-4	hematuria	MESH:D006417	marker/mechanism	8602639

FDA approved drug and dosage information(Total Drugs:7)
DiseaseID	Drug_name	active_ingredients	strength	Dosage Form/Route	Marketing Status	TE code	RLD	RS
MESH:D006417	prilosec	omeprazole	20MG Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons	CAPSULE, DELAYED REL PELLETS;ORAL	Discontinued	None	Yes	No
MESH:D006417	prilosec	omeprazole	20MG Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons	CAPSULE, DELAYED REL PELLETS;ORAL	Discontinued	None	Yes	No
MESH:D006417	omeprazole	omeprazole	20MG	TABLET, DELAYED RELEASE;ORAL	Over-the-counter	None	Yes	Yes
MESH:D006417	omeprazole	omeprazole	20MG	TABLET, DELAYED RELEASE;ORAL	Over-the-counter	None	Yes	Yes
MESH:D006417	busulfex	busulfan	6MG/ML	INJECTABLE;INJECTION	Prescription	AP	Yes	Yes
MESH:D006417	cipro	ciprofloxacin	400MG/40ML (10MG/ML)	INJECTABLE;INJECTION	Discontinued	None	Yes	No
MESH:D006417	cipro	ciprofloxacin	250MG/5ML	FOR SUSPENSION;ORAL	Prescription	AB	Yes	No

FDA labeling changes(Total Drugs:7)
DiseaseID	Pediatric_Labeling_Date	Trade_Name	Generic_Name_or_Proper_Name	Indications Studied	Label Changes Summary	Product Labeling	BPCA(B)	PREA(P)	BPCA(B) and PREA(P)	Pediatric Rule (R)	Sponsor	Pediatric Exclusivity Granted Date	NNPS
MESH:D006417	12/7/2002	prilosec	omeprazole	Gastroesophageal reflux and erosive esophagitis	Safety and effectiveness established in pediatric patients 2-16 years of age Information on dose, PK parameters, exposure/response and AE profile	Labeling	B	-	-	-	AstraZeneca	-	FALSE'
MESH:D006417	03/20/2008	prilosec	omeprazole	Maintenance healing of erosive esophagitis	Efficacy was extrapolated from adults and older children to 1 to 2 year olds and supported with an open-label trial Unique adverse reactions in pediatric patients included increased respiratory system adverse events and fever. Safety and effectiveness in children less than 1 year of age have not been established Dosing and administration information provided for patients 1 year and older weighing at least 5 kg. New dosage form	Labeling	-	-	B, P	-	AstraZeneca	1/5/2001	FALSE'
MESH:D006417	12/7/2002	prilosec	omeprazole	Gastroesophageal reflux and erosive esophagitis	Safety and effectiveness established in pediatric patients 2-16 years of age Information on dose, PK parameters, exposure/response and AE profile	Labeling	B	-	-	-	AstraZeneca	-	FALSE'
MESH:D006417	03/20/2008	prilosec	omeprazole	Maintenance healing of erosive esophagitis	Efficacy was extrapolated from adults and older children to 1 to 2 year olds and supported with an open-label trial Unique adverse reactions in pediatric patients included increased respiratory system adverse events and fever. Safety and effectiveness in children less than 1 year of age have not been established Dosing and administration information provided for patients 1 year and older weighing at least 5 kg. New dosage form	Labeling	-	-	B, P	-	AstraZeneca	1/5/2001	FALSE'
MESH:D006417	01/13/2003	busulfex	busulfan	Part of a conditioning regimen administered prior to hematopoietic progenitor cell transplantation for a variety of malignant hematologic or non-malignant diseases	The population pharmacokinetic estimates of busulfan for clearance and volume of distribution were determined in an open-label, uncontrolled PK study in 24 pediatric patients 5 months to 16 years who received busulfan as part of a conditioning regimen administered prior to hematopoietic progenitor cell transplantation for a variety of malignant hematologic or non-malignant diseases Suggested dosing regimen	Labeling	B	-	-	-	Orphan Medical	12/3/2002	FALSE'
MESH:D006417	03/25/2004	cipro	ciprofloxacin	Complicated UTI and pyelonephritis	Indicated for the treatment of complicated urinary tract infections (cUTIs) and pyelonephritis in pediatric patients 1 17 years of age Not drug of first choice due to increased adverse events compared to controls including events related to joints and/or surrounding tissues Information on PK and dose in pediatric patients 1 17 years of age The most frequent adverse events observed within 6 weeks of treatment initiation during the cUTI clinical trial were gastrointestinal 15% compared to 9% and musculoskeletal 9.3% compared to 6% in ciprofloxacin-treated compared to control-treated patients, respectively	Labeling	B	-	-	-	Bayer	12/18/2003	FALSE'
MESH:D006417	03/25/2004	cipro	ciprofloxacin	Complicated UTI and pyelonephritis	Indicated for the treatment of complicated urinary tract infections (cUTIs) and pyelonephritis in pediatric patients 1 17 years of age Not drug of first choice due to increased adverse events compared to controls including events related to joints and/or surrounding tissues Information on PK and dose in pediatric patients 1 17 years of age The most frequent adverse events observed within 6 weeks of treatment initiation during the cUTI clinical trial were gastrointestinal 15% compared to 9% and musculoskeletal 9.3% compared to 6% in ciprofloxacin-treated compared to control-treated patients, respectively	Labeling	B	-	-	-	Bayer	12/18/2003	FALSE'